(Q38478590)

3 September 2017

Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer (English)

1 reference

3 September 2017

0 references

Eun-Kyu Kim

1

1 reference

3 September 2017

Hyun-Ah Kim

2

1 reference

3 September 2017

Jae Soo Koh

3

1 reference

3 September 2017

Min Suk Kim

4

1 reference

3 September 2017

Kwan-Il Kim

5

1 reference

3 September 2017

Jong Inn Lee

6

1 reference

3 September 2017

Nan Mo Moon

7

1 reference

3 September 2017

Eunyoung Ko

8

1 reference

3 September 2017

Woo Chul Noh

9

1 reference

3 September 2017

language of work or name

English

0 references

publication date

24 December 2010

1 reference

Breast Cancer Research and Treatment

3 September 2017

1 reference

3 September 2017

126

1 reference

3 September 2017

93-99

1 reference

3 September 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-010-1315-z

3 September 2017

0 references

cites work

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

The role of mTOR in the management of solid tumors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Targeting the molecular target of rapamycin (mTOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Determinants of rapamycin sensitivity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Therapeutic targets: MTOR and related pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Akt kinases in breast cancer and the results of adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

The association between Akt activation and resistance to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Metformin: a therapeutic opportunity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1315-Z

10.1007/S10549-010-1315-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

0 references

1 reference